- Home
- ACIU vs HYI Comparison
ACIU vs HYI Comparison
Compare ACIU & HYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- HYI
- Stock Information
- Founded
- ACIU 2003
- HYI 2010
- Country
- ACIU Switzerland
- HYI United States
- Employees
- ACIU N/A
- HYI N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- HYI Investment Managers
- Sector
- ACIU Health Care
- HYI Finance
- Exchange
- ACIU Nasdaq
- HYI Nasdaq
- Market Cap
- ACIU 332.4M
- HYI 279.2M
- IPO Year
- ACIU 2016
- HYI N/A
- Fundamental
- Price
- ACIU $2.68
- HYI $11.95
- Analyst Decision
- ACIU Strong Buy
- HYI
- Analyst Count
- ACIU 2
- HYI 0
- Target Price
- ACIU $12.00
- HYI N/A
- AVG Volume (30 Days)
- ACIU 132.5K
- HYI 50.6K
- Earning Date
- ACIU 11-05-2024
- HYI 01-01-0001
- Dividend Yield
- ACIU N/A
- HYI 9.59%
- EPS Growth
- ACIU N/A
- HYI N/A
- EPS
- ACIU N/A
- HYI N/A
- Revenue
- ACIU $48,505,404.00
- HYI N/A
- Revenue This Year
- ACIU $85.33
- HYI N/A
- Revenue Next Year
- ACIU $80.69
- HYI N/A
- P/E Ratio
- ACIU N/A
- HYI N/A
- Revenue Growth
- ACIU 4097200.00
- HYI N/A
- 52 Week Low
- ACIU $2.25
- HYI $10.99
- 52 Week High
- ACIU $5.14
- HYI $12.24
- Technical
- Relative Strength Index (RSI)
- ACIU 27.49
- HYI 38.04
- Support Level
- ACIU $2.62
- HYI $11.82
- Resistance Level
- ACIU $3.02
- HYI $12.06
- Average True Range (ATR)
- ACIU 0.15
- HYI 0.09
- MACD
- ACIU -0.05
- HYI -0.02
- Stochastic Oscillator
- ACIU 9.52
- HYI 28.26
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About HYI Western Asset High Yield Defined Opportunity Fund Inc.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. It invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.